-
-
-
-
-
-
-
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
-
-
-
-
-
-
-
HUTCHMED Announces Pricing of Global Offering
-
-
-
-
-
-
-
Hutchison China MediTech (HCM) Prices 4.4M ADS Offering at $25/ADS
-
-
-
-
-
-
-
Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering of American Depositary Shares
-
-
-
-
-
-
-
Hutchison China MediTech (HCM) Prices 9.886M ADS at $26.50/Sh
-
-
-
-
-
-
-
Hutchison China MediTech Limited Announces Exercise of Overallotment Option
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

